Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01074411
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:12.079729+00:00
Published At
2019-08-09T00:00:00+00:00
Record Updated At
2019-08-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-08-09"
protocolSection.identificationModule.nctId
"NCT01074411"
protocolSection.identificationModule.officialTitle
"A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Fallopian Tube Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Brenner Tumor (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Clear Cell Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Mucinous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Seromucinous Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Serous Cystadenocarcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Transitional Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)
  • Undifferentiated Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Undifferentiated Ovarian Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.